Clorox Q3 FY2023: adj EPS +15%, net sales +6%, raises full-year outlook

CLOROX CO /DE/

2023-Q3 EPS reported -$0.22 revenue$5,370,000,000

Net sales $1.91B (+6% YoY); organic sales +8%; gross margin 41.8% (+590 bps).
Adjusted EPS $1.51 (+15% YoY); GAAP diluted EPS loss $1.71 due to $445M impairment in vitamins.
YTD operating cash flow $728M, up 61% YoY; free cash flow $584M, 10.9% of sales.
Health & Wellness segment volume -16% but price/mix +23%; Lifestyle sales +15%.
Company raises FY2023 outlook citing pricing, cost savings, and strategic investments.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

CLOROX CO /DE/ reported third quarter ended March 31, 2023 results: revenue $1.91 billion, EPS (a noncash impairment charge of $445 million ($362 million after tax or $2.92) ...). Guidance raised.

Period: third quarter ended March 31, 2023
Revenue: $1.91 billion
EPS: (a noncash impairment charge of $445 million ($362 million after tax or $2.92) ...)
Guidance: raised
Result: reported results

Exact text from the filing

Summary Following is a summary of key third-quarter results. All comparisons are with the third quarter of fiscal year 2022 unless otherwise stated. • Net sales increased 6% to $1.91 billion compared to a 2% net sales increase in the year-ago quarter. The net sales increase was driven largely by favorable price mix, partially offset by lower volume. Organic sales 1

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

CLOROX CO /DE/ filing history →

Source: SEC EDGAR

accession 0000021076-23-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.